Skip to main content
Premium Trial:

Request an Annual Quote

Richard De Schutter, Bijan Almassian, Pierre Cassigneul

Premium

Richard De Schutter has been elected chairman of Incyte’s board of directors, the Palo Alto, Calif. company said earlier this week.

De Schutter, who has served on Incyte’s board since January 2002, was previously chairman and CEO of DuPont pharmaceuticals from January to October 2001. Prior to holding the DuPont position, De Schutter was vice-chairman, chief administrative officer and a director at Monsanto, after Monsanto acquired Searle, where De Schutter had been chairman and CEO.

Currently De Schutter also serves on the boards of Smith & Nephew, General Binding, and Varian.


Bijan Almassian has been ap-pointed chief operating officer of Panacea Pharmaceuticals. Almasian comes to Panacea, a Gaithersburg, Md. genomics- and proteomics-based diagnostics and therapeutics company, from AlexiaPharma, a pain and obesity therapeutics developer based in New Haven, Conn., where he served as president and COO. Almassian has held previous management positions at Vion Pharmaceuticals, GeneLabs, Genzyme/Integrated Genetics, Instrumentation Laboratories, and Orion Research. He received a PhD from Massachusetts College of Pharmacy, and completed postdoctoral training at Boston University Medical School.


Jeffrey Saffer has been appointed president of OmniViz., a firm that makes genomic visualization software.

Saffer has been chief technology officer of the company since its spinoff from Battelle in 2000, and will continue in this role.

Prior to joining the Maynard, Mass. startup, Saffer was manager of the molecular biosciences department at Pacific Northwest National Laboratory, which is managed by Battelle. AT PNNL, Saffer developed the gene expression visualization techniques that led to the development of the OmniViz software and the spinout of the company. Saffer has also worked at the Jackson Laboratory and the NCI Laboratory of Biochemistry.


Diagnostics industry veteran Pierre Cassigneul has been appointed operating partner of biopharma and bio-IT consulting firm Stone Bridge management, of Pittstown, N.J. Cassigneul comes to the firm from Becton Dickinson, where he was vice president of diabetesmanagement.

Previously, Cassigneul was senior vice president of Bayer, and general manager of the company’s diabetes self-testing arm. He has also served in leadership roles at Ortho Diagnostic Systems’ AIDS and hepatitis business unit, and Abbott Laboratories; and held a market research position at Eurequip in Paris.

 

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.